| Editor's Note: Fierce Biotech will not publish Monday, Jan. 15 for Martin Luther King Jr. Day. We’ll be back in your inboxes Tuesday! |
Today’s Big NewsJan 12, 2024 |
|
Tuesday, January 23, 2024 | 11am ET / 8am PT Join a cutting-edge conversation on January 23, 2024 with Real Chemistry and Quid as they explore how their partnership has forged a deeper understanding of patient insights. Register now. 
|
|
| By Angus Liu As one of the first Big Pharmas to embrace antibody-drug conjugates, Roche plans to bet more on the popular cancer modality, Global Head of Pharma Partnering James Sabry, Ph.D., told Fierce. But biotechs looking for a Roche alliance must first meet an invisible bar. |
|
|
|
By Annalee Armstrong Sometimes, you have to act while the tea is hot. For Roivant CEO Matt Gline, that meant dealing out Telavant to Roche for $7.1 billion last year, even if he wasn’t quite ready to let the vant company go. |
By Nick Paul Taylor Reuters and The Wall Street Journal have punctured investors’ hopes that Novartis will buy Cytokinetics. The Swiss drugmaker has reportedly backed away from the potential deal late in negotiations, deflating the biotech’s share price. |
By Annalee Armstrong The biotech industry has a love-hate relationship with the J.P. Morgan Healthcare Conference in San Francisco. Every year, thousands gather on the Golden Gate City and battle rain, hail, floods, what have you, just to make billion-dollar deals. |
By Andrea Park,Zoey Becker Mark Alles, who's spent the better part of the last four decades in biopharma leadership roles, has been named chairman and CEO of TORL BioTherapeutics. |
By Helen Floersh Researchers have chipped away a little more at the mystery of cancer resistance, this time in the form of new findings that explain how the immune system senses DNA damage in precancerous cells. The results could offer paths not only to treatments, but even prevention. |
By Kevin Dunleavy A preliminary evaluation by the FDA found no evidence that use of popular diabetes and weight-loss drugs from Novo Nordisk and Eli Lilly can cause suicidal thoughts, the U.S. regulator said. |
By Ben Adams Rare disease specialist BioMarin has a new CEO in Genentech’s former chief Alexander Hardy and he appears to be shaking up his commercial team as its lead Jeffrey Ajer will now leave the company by July. |
By Andrea Park ResMed first warned in November that some of the masks used with its CPAP machines contain magnets that could potentially interfere with pacemakers, neurostimulators and other implanted medical devices. |
By Heather Landi "For healthcare, the biggest issue right now is IP [intellectual property] protection and the way access to information may change going forward," entrepreneur Mark Cuban said during a CES panel. |
By Conor Hale Described as a virtual microscope, the BrainSee program could be used before a PET scan or biopsies of cerebrospinal fluid, according to the developer Darmiyan. |
By Zoey Becker Pfizer mused on ADC opportunities in China, while Takeda's R&D head revealed details behind the company's competitive TYK2 deal with Nimbus at this year's J.P. Morgan Healthcare Conference. Astellas received a manufacturing-related rejection for its gastric cancer candidate. And more. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. |
|
|---|
|
|
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper The road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| |
|
